Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has presented new clinical study results for its TROP2 antibody-drug conjugate $(ADC)$, sacituzumab tirumotecan (sac-TMT), at the 2025 Chinese Congress on Holistic Integrative Oncology (CCHIO), held in Kunming, Yunnan from November 6 to 9, 2025. The company reported preliminary data from a Phase II trial evaluating sac-TMT in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations. Among 42 patients, the objective response rate $(ORR)$ was 35.7%, with a disease control rate (DCR) of 85.7% and a median progression-free survival (mPFS) of 9.5 months. Additionally, results from a non-squamous NSCLC cohort in a Phase II study combining sac-TMT with tagitanlimab (an anti-PD-L1 antibody) as first-line therapy were presented. Among 81 patients, the confirmed ORR was 59.3%, DCR was 91.4%, and median progression-free survival reached 15.0 months. No treatment-related adverse events led to discontinuation or death. These results were presented as oral presentations at the conference.